

Global Cardiovascular Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/GA87EB6B343EN.html>

Date: November 2024

Pages: 105

Price: US\$ 3,480.00 (Single User License)

ID: GA87EB6B343EN

Abstracts

According to our (Global Info Research) latest study, the global Cardiovascular Drugs market size was valued at USD 6189 million in 2023 and is forecast to a readjusted size of USD 6525.7 million by 2030 with a CAGR of 0.8% during review period.

Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive

to emerging public health needs.

The Global Info Research report includes an overview of the development of the Cardiovascular Drugs industry chain, the market status of Hypertension (Renin-Angiotensin System Blockers, Beta Blockers), Hyperlipidemia (Renin-Angiotensin System Blockers, Beta Blockers), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Cardiovascular Drugs.

Regionally, the report analyzes the Cardiovascular Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Cardiovascular Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Cardiovascular Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Cardiovascular Drugs industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Renin-Angiotensin System Blockers, Beta Blockers).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Cardiovascular Drugs market.

Regional Analysis: The report involves examining the Cardiovascular Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future

projections and forecasts for the Cardiovascular Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Cardiovascular Drugs:

Company Analysis: Report covers individual Cardiovascular Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Cardiovascular Drugs. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hypertension, Hyperlipidemia).

Technology Analysis: Report covers specific technologies relevant to Cardiovascular Drugs. It assesses the current state, advancements, and potential future developments in Cardiovascular Drugs areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Cardiovascular Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Cardiovascular Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type

Renin-Angiotensin System Blockers

Beta Blockers

Diuretics

Anti-Clotting Agents

Antihyperlipidemic

Market segment by Application

Hypertension

Hyperlipidemia

Major players covered

Amgen

AstraZeneca

Bayer

Bristol Myers Squibb and Pfizer

Daiichi Sankyo

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Portola

Sanofi

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Cardiovascular Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Cardiovascular Drugs, with price, sales, revenue and global market share of Cardiovascular Drugs from 2019 to 2024.

Chapter 3, the Cardiovascular Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Cardiovascular Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023. and Cardiovascular Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Cardiovascular Drugs.

Chapter 14 and 15, to describe Cardiovascular Drugs sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Cardiovascular Drugs

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Cardiovascular Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030

1.3.2 Renin-Angiotensin System Blockers

1.3.3 Beta Blockers

1.3.4 Diuretics

1.3.5 Anti-Clotting Agents

1.3.6 Antihyperlipidemic

1.4 Market Analysis by Application

1.4.1 Overview: Global Cardiovascular Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030

1.4.2 Hypertension

1.4.3 Hyperlipidemia

1.5 Global Cardiovascular Drugs Market Size & Forecast

1.5.1 Global Cardiovascular Drugs Consumption Value (2019 & 2023 & 2030)

1.5.2 Global Cardiovascular Drugs Sales Quantity (2019-2030)

1.5.3 Global Cardiovascular Drugs Average Price (2019-2030)

2 MANUFACTURERS PROFILES

2.1 Amgen

2.1.1 Amgen Details

2.1.2 Amgen Major Business

2.1.3 Amgen Cardiovascular Drugs Product and Services

2.1.4 Amgen Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

2.1.5 Amgen Recent Developments/Updates

2.2 AstraZeneca

2.2.1 AstraZeneca Details

2.2.2 AstraZeneca Major Business

2.2.3 AstraZeneca Cardiovascular Drugs Product and Services

2.2.4 AstraZeneca Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)

- 2.2.5 AstraZeneca Recent Developments/Updates
- 2.3 Bayer
 - 2.3.1 Bayer Details
 - 2.3.2 Bayer Major Business
 - 2.3.3 Bayer Cardiovascular Drugs Product and Services
 - 2.3.4 Bayer Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.3.5 Bayer Recent Developments/Updates
- 2.4 Bristol Myers Squibb and Pfizer
 - 2.4.1 Bristol Myers Squibb and Pfizer Details
 - 2.4.2 Bristol Myers Squibb and Pfizer Major Business
 - 2.4.3 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Product and Services
 - 2.4.4 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.4.5 Bristol Myers Squibb and Pfizer Recent Developments/Updates
- 2.5 Daiichi Sankyo
 - 2.5.1 Daiichi Sankyo Details
 - 2.5.2 Daiichi Sankyo Major Business
 - 2.5.3 Daiichi Sankyo Cardiovascular Drugs Product and Services
 - 2.5.4 Daiichi Sankyo Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.5.5 Daiichi Sankyo Recent Developments/Updates
- 2.6 Johnson & Johnson
 - 2.6.1 Johnson & Johnson Details
 - 2.6.2 Johnson & Johnson Major Business
 - 2.6.3 Johnson & Johnson Cardiovascular Drugs Product and Services
 - 2.6.4 Johnson & Johnson Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.6.5 Johnson & Johnson Recent Developments/Updates
- 2.7 Merck & Co.
 - 2.7.1 Merck & Co. Details
 - 2.7.2 Merck & Co. Major Business
 - 2.7.3 Merck & Co. Cardiovascular Drugs Product and Services
 - 2.7.4 Merck & Co. Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.7.5 Merck & Co. Recent Developments/Updates
- 2.8 Novartis
 - 2.8.1 Novartis Details
 - 2.8.2 Novartis Major Business

- 2.8.3 Novartis Cardiovascular Drugs Product and Services
- 2.8.4 Novartis Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Novartis Recent Developments/Updates
- 2.9 Pfizer
 - 2.9.1 Pfizer Details
 - 2.9.2 Pfizer Major Business
 - 2.9.3 Pfizer Cardiovascular Drugs Product and Services
 - 2.9.4 Pfizer Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.9.5 Pfizer Recent Developments/Updates
- 2.10 Portola
 - 2.10.1 Portola Details
 - 2.10.2 Portola Major Business
 - 2.10.3 Portola Cardiovascular Drugs Product and Services
 - 2.10.4 Portola Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.10.5 Portola Recent Developments/Updates
- 2.11 Sanofi
 - 2.11.1 Sanofi Details
 - 2.11.2 Sanofi Major Business
 - 2.11.3 Sanofi Cardiovascular Drugs Product and Services
 - 2.11.4 Sanofi Cardiovascular Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
 - 2.11.5 Sanofi Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: CARDIOVASCULAR DRUGS BY MANUFACTURER

- 3.1 Global Cardiovascular Drugs Sales Quantity by Manufacturer (2019-2024)
- 3.2 Global Cardiovascular Drugs Revenue by Manufacturer (2019-2024)
- 3.3 Global Cardiovascular Drugs Average Price by Manufacturer (2019-2024)
- 3.4 Market Share Analysis (2023)
 - 3.4.1 Producer Shipments of Cardiovascular Drugs by Manufacturer Revenue (\$MM) and Market Share (%): 2023
 - 3.4.2 Top 3 Cardiovascular Drugs Manufacturer Market Share in 2023
 - 3.4.2 Top 6 Cardiovascular Drugs Manufacturer Market Share in 2023
- 3.5 Cardiovascular Drugs Market: Overall Company Footprint Analysis
 - 3.5.1 Cardiovascular Drugs Market: Region Footprint

- 3.5.2 Cardiovascular Drugs Market: Company Product Type Footprint
- 3.5.3 Cardiovascular Drugs Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Cardiovascular Drugs Market Size by Region
 - 4.1.1 Global Cardiovascular Drugs Sales Quantity by Region (2019-2030)
 - 4.1.2 Global Cardiovascular Drugs Consumption Value by Region (2019-2030)
 - 4.1.3 Global Cardiovascular Drugs Average Price by Region (2019-2030)
- 4.2 North America Cardiovascular Drugs Consumption Value (2019-2030)
- 4.3 Europe Cardiovascular Drugs Consumption Value (2019-2030)
- 4.4 Asia-Pacific Cardiovascular Drugs Consumption Value (2019-2030)
- 4.5 South America Cardiovascular Drugs Consumption Value (2019-2030)
- 4.6 Middle East and Africa Cardiovascular Drugs Consumption Value (2019-2030)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Cardiovascular Drugs Sales Quantity by Type (2019-2030)
- 5.2 Global Cardiovascular Drugs Consumption Value by Type (2019-2030)
- 5.3 Global Cardiovascular Drugs Average Price by Type (2019-2030)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Cardiovascular Drugs Sales Quantity by Application (2019-2030)
- 6.2 Global Cardiovascular Drugs Consumption Value by Application (2019-2030)
- 6.3 Global Cardiovascular Drugs Average Price by Application (2019-2030)

7 NORTH AMERICA

- 7.1 North America Cardiovascular Drugs Sales Quantity by Type (2019-2030)
- 7.2 North America Cardiovascular Drugs Sales Quantity by Application (2019-2030)
- 7.3 North America Cardiovascular Drugs Market Size by Country
 - 7.3.1 North America Cardiovascular Drugs Sales Quantity by Country (2019-2030)
 - 7.3.2 North America Cardiovascular Drugs Consumption Value by Country (2019-2030)
 - 7.3.3 United States Market Size and Forecast (2019-2030)
 - 7.3.4 Canada Market Size and Forecast (2019-2030)

7.3.5 Mexico Market Size and Forecast (2019-2030)

8 EUROPE

8.1 Europe Cardiovascular Drugs Sales Quantity by Type (2019-2030)

8.2 Europe Cardiovascular Drugs Sales Quantity by Application (2019-2030)

8.3 Europe Cardiovascular Drugs Market Size by Country

8.3.1 Europe Cardiovascular Drugs Sales Quantity by Country (2019-2030)

8.3.2 Europe Cardiovascular Drugs Consumption Value by Country (2019-2030)

8.3.3 Germany Market Size and Forecast (2019-2030)

8.3.4 France Market Size and Forecast (2019-2030)

8.3.5 United Kingdom Market Size and Forecast (2019-2030)

8.3.6 Russia Market Size and Forecast (2019-2030)

8.3.7 Italy Market Size and Forecast (2019-2030)

9 ASIA-PACIFIC

9.1 Asia-Pacific Cardiovascular Drugs Sales Quantity by Type (2019-2030)

9.2 Asia-Pacific Cardiovascular Drugs Sales Quantity by Application (2019-2030)

9.3 Asia-Pacific Cardiovascular Drugs Market Size by Region

9.3.1 Asia-Pacific Cardiovascular Drugs Sales Quantity by Region (2019-2030)

9.3.2 Asia-Pacific Cardiovascular Drugs Consumption Value by Region (2019-2030)

9.3.3 China Market Size and Forecast (2019-2030)

9.3.4 Japan Market Size and Forecast (2019-2030)

9.3.5 Korea Market Size and Forecast (2019-2030)

9.3.6 India Market Size and Forecast (2019-2030)

9.3.7 Southeast Asia Market Size and Forecast (2019-2030)

9.3.8 Australia Market Size and Forecast (2019-2030)

10 SOUTH AMERICA

10.1 South America Cardiovascular Drugs Sales Quantity by Type (2019-2030)

10.2 South America Cardiovascular Drugs Sales Quantity by Application (2019-2030)

10.3 South America Cardiovascular Drugs Market Size by Country

10.3.1 South America Cardiovascular Drugs Sales Quantity by Country (2019-2030)

10.3.2 South America Cardiovascular Drugs Consumption Value by Country (2019-2030)

10.3.3 Brazil Market Size and Forecast (2019-2030)

10.3.4 Argentina Market Size and Forecast (2019-2030)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Cardiovascular Drugs Sales Quantity by Type (2019-2030)

11.2 Middle East & Africa Cardiovascular Drugs Sales Quantity by Application (2019-2030)

11.3 Middle East & Africa Cardiovascular Drugs Market Size by Country

11.3.1 Middle East & Africa Cardiovascular Drugs Sales Quantity by Country (2019-2030)

11.3.2 Middle East & Africa Cardiovascular Drugs Consumption Value by Country (2019-2030)

11.3.3 Turkey Market Size and Forecast (2019-2030)

11.3.4 Egypt Market Size and Forecast (2019-2030)

11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)

11.3.6 South Africa Market Size and Forecast (2019-2030)

12 MARKET DYNAMICS

12.1 Cardiovascular Drugs Market Drivers

12.2 Cardiovascular Drugs Market Restraints

12.3 Cardiovascular Drugs Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Cardiovascular Drugs and Key Manufacturers

13.2 Manufacturing Costs Percentage of Cardiovascular Drugs

13.3 Cardiovascular Drugs Production Process

13.4 Cardiovascular Drugs Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

- 14.1.2 Distributors
- 14.2 Cardiovascular Drugs Typical Distributors
- 14.3 Cardiovascular Drugs Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer

List Of Tables

LIST OF TABLES

List Of Figures

LIST OF FIGURES

I would like to order

Product name: Global Cardiovascular Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/GA87EB6B343EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA87EB6B343EN.html>